All In Biotech

Drug Trial Radar · NCT03182244

A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation

Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation

Last checked: Nov 20, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 276 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

276

Actual

Start

Oct 25, 2017

Primary completion

Dec 25, 2023

Study completion Jul 29, 2026

Sponsor

Lead sponsor
Astellas Pharma IncAstellas (ALPMY)
Sponsor type
Industry
First posted
Jun 9, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to determine the clinical benefit of ASP2215 therapy in participants with FMS-like tyrosine kinase (FLT3) mutated AML who were refractory to or had relapse after first-line AML therapy as shown with overall survival (OS) compared to salvage chemotherapy. In addition, this study evaluated safety as well as determined the overall efficacy in event-free survival (EFS) and complete remission (CR) rate of ASP2215 compared to salvage chemotherapy.

Conditions

  • AML With FLT3 Mutation

Interventions

  • GilteritinibDrug

    Tablet administered orally once daily.

  • CytarabineDrug

    Once/twice daily Intravenously (IV)/subcutaneously (SC).

  • MitoxantroneDrug

    Once daily IV injection.

  • EtoposideDrug

    Once daily IV injection.

  • G-CSFDrug

    Once daily IV/SC injection.

  • FludarabineDrug

    Once daily IV injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: From the date of randomization up to the date of death (up to approximatley 74 months)

Locations

49 sites in 5 countries. Site status is shown where the registry gives one.

  • Site CN103

    Beijing, China

  • Site CN108

    Beijing, China

  • Site CN109

    Beijing, China

  • Site CN110

    Beijing, China

  • Site CN131

    Beijing, China

  • Site CN116

    Changchun, China

  • Site CN120

    Changsha, China

  • Site CN119

    Fuzhou, China

  • Site CN102

    Guangzhou, China

  • Site CN114

    Guangzhou, China

  • Site CN121

    Guangzhou, China

  • Site CN130

    Guiyang, China

  • Site CN107

    Hangzhou, China

  • Site CN118

    Hefei, China

  • Site CN123

    Huangpu Qu, China

  • Site CN117

    Jinan, China

  • Site CN133

    Lanzhou, China

  • Site CN128

    Nanjing, China

  • Site CN106

    Qingdao, China

  • Site CN126

    Shanghai, China

  • Site CN129

    Shanghai, China

  • Site CN125

    Shenyang, China

  • Site CN101

    Tianjin, China

  • Site CN105

    Wuhan, China

  • Site CN122

    Xi'an, China

  • Site CN132

    Zhangzhou, China

  • Site CN113

    Zhengzhou, China

  • Site CN136

    Zhengzhou, China

  • Site MY306

    Ampang, Malaysia

  • Site MY305

    George Town, Malaysia

  • Site MY301

    Johor Bahru, Malaysia

  • Site MY304

    Kota Kinabalu, Malaysia

  • Site MY302

    Kuala Lumpur, Malaysia

  • Site MY303

    Pulau Pinang, Malaysia

  • Site RU506

    Kemerovo, Russia

  • Site RU504

    Krasnoyarsk, Russia

  • Site RU508

    Moscow, Russia

  • Site RU509

    Moscow, Russia

  • Site RU501

    Saint Petersburg, Russia

  • Site RU502

    Saint Petersburg, Russia

Showing 40 of 49 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.